StudyFinder
HM2024-04: A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Recruiting
This study is for patients with Chronic Lymphocytic Leukemia (CLL) that have not had any treatment yet. Study participants have an equal chance of either receiving a standard of care treatment (venetoclax plus obinutuzumab) or the combination of investigational drugs being studied (sonrotoclax plus zanubrutinib). The goal is to discover whether sonrotoclax plus zanubrutinib is more effective than the current standard of care treatments.
Male or Female
18 years and over
Inclusion Criteria:
• new diagnosis of Chronic Lymphocytic Anemia (CLL) that has not been treated but requires treatment
• at least up walking and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:
• CLL has been previously treated
• known central nervous system involvement
• confirmed progressive multifocal leukoencephalopathy (PML)
• uncontrolled hypertension
Drug: Obinutuzumab, Drug: Sonrotoclax, Drug: Venetoclax, Drug: Zanubrutinib
Cancer
Clinics and Surgery Center (CSC), Chronic Lymphocytic Anemia, CLL
Sanjal Desai - desai171@umn.edu
Sanjal Desai
PHASE3
STUDY00021639
See this study on ClinicalTrials.gov